Food and Drug Administration
Briefing Information
Exploration
of Issues Related to FDA’s Risk Assessment Program for Marketed Drugs
Disclaimer
Portions of this document have been determined to be exempt from
disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. ยง552).
These redacted portions will appear as white space on the screen or on
the printed page.